Innovative Medicines Initiative
|
|
- Marion Small
- 6 years ago
- Views:
Transcription
1 Innovative Medicines Initiative
2 Innovative Medicines Initiative: Joining forces in the healthcare sector The European Union and the pharmaceutical industry have joined forces to make drug R&D processes in Europe more innovative and efficient, enhance Europe s competitiveness & address key societal challenges by forming the biggest PPP in Life Science 2
3 Public-Private Partnerships: Why? Pooling expertise, knowledge and resources Developing incentives to address major unmet medical needs Providing a neutral trusted platform to align public and private interests
4 IMI accelerates the development of new therapies for major yet unmet public health needs and diseases where treatments are lacking
5 The Anti-Microbial Resistance Conundrum - Anti-microbial resistance kills European citizens every year - Annual costs are estimated at 1.5 billion - Only 2 new antibiotic classes developed over the last 30 years - Low level of industry investments in antibiotic innovation
6 How IMI addresses infectious diseases Invested 229 million in projects aiming at: Solving scientific challenges Fostering new models of industrial collaborations for antibiotics and diagnostics development Developing networks for clinical trials Revisiting regulatory environment Providing necessary incentives for industry to reinvest in the area
7 COMBACTE CLIN-Network 280 members and Candidate members
8 Improved detection of infectious diseases 5 EFPIA companies; 10 Public organizations; 4 SME Total Budget: 14.4 Mi RAPP-ID is developing Point-of-Care Tests (POCTs) for rapid (hospital <2h, primary care <30min) detection of bacteria, mycobacteria, fungi and viruses Developed conceptual POCTs platforms for community-acquired pneumonia, influenza, tuberculosis Designed conceptual POCs for the detection of antibiotic resistance for Ventilator-Associated Pneumonia and tuberculosis Developed a diagnostic device and protocol related to breath-born aerosol sampling - patent application filed Concept RCA module chip
9 The conundrum of brain disorders Brain disorders affect 1 in 3 Europeans And cost the economy 798 billion / year Developing new drugs to treat brain disorders takes longer, costs more than for other diseases There are few effective treatments in this area IMI projects are tackling these issues
10 How IMI addresses brain disorders Invested 148 million in projects aiming at: Shedding new light on the underlying causes of autism (EU-AIMS) Combining data to pave the way for new treatments for schizophrenia & depression (NEWMEDS) Identifying new targets for drugs for chronic pain (Europain) Developing models to predict the efficacy of drug candidates in Alzheimer s patients (PHARMACOG) Revisiting regulatory environment for drug development Providing necessary incentives for industry to reinvest in brain disorders
11 Advances in Autism 6 EFPIA companies; 15 Public organizations; 3 SME 1 patient org; Total Budget: 35.9 Mi Identified brain functional abnormalities that can be reversed in ASD patients by modulating brain 5HT - outcome predictor for clinical trials Identified significant differences in cortico-cortical anatomical connectivity in ASD patients - outcome predictor for clinical trials Identified significant differences in brain functional response to emotional sounds in infants at risk for autism - risk predictor Published first study of EU wide prescribing in ASD
12 2 Largest Clinical Trials for Early Detection and Monitoring of ASD Children Identification of biomarkers that precede ASD onset Prospective study of 300 high-risk infants (3 and 7 months) with older siblings with ASD, and 100 low-risk Infant cognition, behavior, neuroimaging, neurophysiology Relation to symptoms/diagnosis of ASD at outcome Accelerated longitudinal study for validation of ASD biomarkers in children and adults 450 ASD patients and 300 controls magnetic resonance imaging, event-related potential, eyetracking
13 Preclinical Alzheimer s disease 9 EFPIA companies; 36 Public organizations; 7 SME 3 patient org.; Total Budget*: 53.4 Mi Findings in preclinical Alzheimer s disease: common in cognitively normal elderly people can be diagnosed by cerebrospinal fluid markers associated with future cognitive decline and mortality therapeutic target * Total budget for the EMIF program that included EMIF AD, EMIF metabolomics and EMIF platform
14 Novel Disease Markers for Alzheimer s Disease 12 EFPIA companies; 13 Public organizations; 5 SME Total Budget: 27.7 Mi Platelets: APP metabolites, 55 kd and 25 kd fragments - AlzProtect Lymphocytes: ~ 150 RNA transcripts related to Abeta pathway, inflammatory pathway and to immune mechanism - Exonhit (now Diaxonhit) Red blood cells: binding of Abeta1-42 on cellular membrane and change in PKC conformation in red blood cells - Innovative Health Diagnostics (IHD) Red blood cells: panel of inflammatory markers- Innovative Concept in Drug Development (ICDD) COMPLETED RECRUITMENT OF 150 MILD COGNITIVE IMPAIRED PATIENTS FOR BIOMARKER MATRIX CLINICAL TRIAL
15 Advances in schizophrenia and depression research 10 EFPIA companies; 7 Public organizations; 3 SME Total Budget: 23.2 Mi Gained novel insights into the biology of schizophrenia Standardised the cognitive models across several industrial partners Developed novel tools for drug discovery - animal models, human imaging Developed new web tools - image analysis, biomarker significance Provided information for the design of more efficient clinical trials
16 Achievements in chronic pain 8 EFPIA companies; 12 Public organizations; 1 SME Total Budget: 18.2 Mi Initiated international consensus meetings on conducting preclinical trials Conducting clinical trials to improve patient stratification Developing tools to predict which patients will respond to treatments Studying the placebo effect to reduce clinical trial failures Initiated EMA interactions to frame regulatory landscape
17 DIABETES: Fighting the epidemic through Public-Private Partnership Major Public Health Need Distrust in past-research Hurdles to drug development Diabetes will affect 43 million Europeans in million spent on 2011 on treating diabetes and its complications Cardiovascular complications of rosiglitazone and benfluorex Patients heterogeneity Lack of reliable markers for disease activity and complications
18 How IMI facilitates the development of new diabetes therapies Invested 125 million in 3 projects aiming at: Solving scientific challenges Developing reliable measures of diabetes activity and complications Developing treatments tailored to the different needs of individual patients
19 Biomarkers of Diabetic Complications 6 EFPIA companies; 18 Public organizations; 1 SME Total Budget: 32.6 Mi Generated the largest ever made database of GWAS samples in diabetic nephropathy (DN) from patients with T1D & T2D - discovery of potential biomarkers Identified multiple biomarker candidates for diabetic related kidney damage, retina damage and coronary vascular disease Developed an ultrasound/radiofrequency-based virtual histology for noninvasive assessment of plaque structure 3 patents in preparation
20 Advances in Diabetes 8 EFPIA companies; 12 Public organizations; 1 SME Total Budget: 25.9 Mi Discovered a lipid signature in the serum of mice fed with high fat diet that correlates with physiological readouts potential biomarker for diabetes Generated the 1 st human ß-cell line (EndoCBeta H1) and its beta cell phenotype maintenance has been confirmed by 3 pharma partners Working on the 2 nd generation human ß-cell lines with excisable immortality genes - more suitable for drug discovery purposes Generated the world largest bio repository of human islets for diabetes research, with a bioinformatical analysis of the genome, transcriptome, lipidome and morphological and physiological characteristics islets
21 IMI DIABETES PLATFORM Memorandum of Understanding between IMIDIA, SUMMIT and DIRECT for exchange of data and confidential information
22 IMI develops better tools to ensure the safety of existing and future medicines
23 Safer and Faster Evidence Based Translation 11 EFPIA companies; 5 Public organizations; 4 SME Total Budget: 35.9 Mi Evaluated 153 potential biomarker candidates for drug-induced injury of the kidney, liver and vascular system 17 exploratory clinical studies started or completed > 6500 retrospective samples collected 64 biomarker assays developed Dialogue with Regulatory Agencies established
24 5 th release of the Vitic Nexus etox database Development of reliable toxicity predictive systems 537 substances (165 confidential) linked to 1,703 study designs (Bayer, Boehringer, Esteve, GlaxoSmithKline, Lundbeck, Novartis, Pfizer, Roche, Sanofi, Servier and UCB) 3 rd release of the ChOX database 411 toxicology-linked targets; 162,287 distinct compounds and 701,181 activities Version 1 of the integration system, etoxsys, was released to all partners 7 out of 10 companies have already a running system. 90 predictive models developed 13 EFPIA companies; 8 Public organizations; 4 SME Total Budget: 13.9 Mi
25 New Methodologies in Pharmacovigilance & Pharmacoepidemiology 12 EFPIA companies; 16 Public organizations; 2 SME Total Budget: 29.8 Mi Aims to strengthen the monitoring of benefit-risk of medicines in Europe by developing innovative methods Works to enhance early detection and assessment of adverse drug reactions from different data sources (clinical trials, spontaneous reporting and observational studies) Is developing methods to enable the integration and visual presentation of data on benefits and risks Delivered PROTECT ADR database of adverse drug reactions (ADRs) ADRs for 654 medicines Delivered the inventory of Drug Consumption Databases in Europe 17 countries
26 IMI provides a unique neutral platform for a continuous dialogue with patients, regulators, academia and industry
27 Since 2009, 40 projects launched - total budget 1.2 billion * *: Estimate
28 Creation of unprecedented collective intelligence networks Collaborative publications among IMI researchers -Call 1-3 Data & analysis: Thomson Reuters (Custom Analytics & IP Solutions)
29 Delivering high quality research Citation Impact by research area 0,0 1,0 2,0 3,0 Pharmacology & Pharmacy Neurosciences Mathematical & Computational Endocrinology & Metabolism Biology Research & Experimental Medicine Clinical Neurology Psychiatry Overall Data & analysis: Thomson Reuters (Custom Analytics & IP Solutions) IMI Projects average EU average
30 Securing regulatory relevance of projects outputs via regulators involvement Regulators represented in IMI projects as: Coordinator: EMA (1); Participants: EMA (1) and other EU national Agencies (5); Advisory Board: EMA (>10) and FDA (5) Informal interactions already established for a number of projects EMA Qualification Advice procedures ongoing for 2 projects IMI referred to the EMA Road Map to 2015 and more specifically highlighted in workprograms of some EMA Working Parties Safety, Pharmacogenomics, Patients and Consumers Organisations IMI/EFPIA held an information session for projects with EMA/FDA on the processes for Drug Development Tools advice and qualification (May 2013)
31 IMI actively involves patients
32 Development of tools to measure physical activity status in COPD 8 EFPIA companies; 7 Public organizations; 1 SME 3 patient org; Total Budget: 16.7 Mi Aim: development of Patient Reported Outcomes that measure aspects of physical activity relevant to patients and are sensitive to changes due to treatment. literature 2 questionnaires patients 6 activity meters 2 meters initial validation (6 wks) reduction integration 230 patients re-assessment 6+12 months for seasonal effects final validation: clinical & behavioural studies
33 Biomarkers for Predicting Severe Asthma Outcome 9 EFPIA companies; 21 Public organizations; 3 SME 5 patient org; Total Budget: 20.1 Mi Established diagnostic criteria on severe asthma Developed various omics platforms based on genetic, proteomic, metabolomic, breathomic biomarkers Generated a preliminary phenotype handprint by combining molecular, histological, clinical and patient-reported data Patient cohort - 14 centres across Europe targeting 1025 subjects, to validate the handprints for their predictive efficacy in gold standard and experimental therapeutic intervention Diagnosis and definition of severe asthma: an international consensus; Bel et al., 2011 An integrative system biology approach to understanding pulmonary diseases; Auffray et al., 2010
34 IMI contributes to the competitiveness of the European pharmaceutical sector
35 IMI improves pharmaceutical R&D productivity 1. Establishment of robust validated models for drug development 2. Identification of new drug targets 3. Tools for predictive toxicology 4. Advances in precision medicine 5. Novel, clinically relevant biomarkers 6. New patient reported outcomes (with regulatory guidance) 7. New tools for big data management, effective data interpretation, and clinical decision support 8. Streamlining of clinical trial design and regulatory frameworks 9. Access and creation of clinical investigator networks 10. Resources for a successful translation - genes to animal models to patients 11. Investment in reclassification of complex diseases
36 Novel in vitro methods for cancer drug discovery 7 EFPIA companies; 7 Public organizations; 4 SME Total Budget: 30.7 Mi Developed cancer organoid cultures - 3D cultures that preserve cancer heterogeneity Completed cancer drug screening 10 drugs on 5 patient derived cell lines each Developed patient derived xenograft cancer models Discovered potential biomarkers able to predict tumor sensitivity to Afatinib (105 BM)and to Regorafenib (69 BM) treatment
37 Targeting Rheumatoid Arthritis 9 EFPIA companies; 24 Public organizations; 1 SME Total Budget: 38.1 Mi Identification and characteristics of cohorts and biobanks for different stages of RA (33 cohorts, more than biosamples) Identification of biomarkers for response to therapy Standardization of existing and development of new animal models Production of monoclonal human antibodies to autoantigenic targets in RA Identification of new targets for therapy, including six potential mir targets that are translatable between mice and RA Stittrich AB et al. Ann Rheum Disdoi: : A /ard , presented at the EWRR 2011
38 Modeling and Simulation Clinical Trial Simulator - Prototype v.2 Flexible study designs for PII clinical drug development: parallel group studies crossover studies complex treatments Simulation of patients sampled Simulating the exposure to the investigational drug Simulating types of drug effects related to drug exposure: Continuous effects Time-to-event effects Categorical effects Count data as effects Methods of evaluating the simulated trials Optimal sampling times Individual probabilities or risks Trial success Automatic reporting 10 EFPIA companies; 10 Public organizations; 5 SME Total Budget: 21.2 Mi
39 1 DESIGN Feasibility Study Efforts to Automate clinical research Protocol (CDISC PRM SDM) 2 EXECUTION Patient Recruitment 10 EFPIA companies; 21 Public organizations; 2 SME Total Budget: 16 Mi 3 EXECUTION Data Collection Case Report Form (CDISC ODM) FDA-EMEA SUBMISSIO N Regulator s XML XML XML Trial Registry Document Manageme nt System Clinical Trial Management System (CTMS) Clinical Data Management System (CDMS) XML
40 IMI trains a new generation of industrial scientists and regulators, and reduces the cost of continuous professional development for companies 38.5 million invested in Education and Training programs More than 1000 scientists have been trained so far Many more scientists take advantage of industrial internships Enhanced learning experience
41 IMI Education and Training programs > 1000 trainees so far Catalogued >5000 masters, PhD, CPD and short courses taught in 21 languages, from 39 countries, covering over 60 scientific, therapeutic and biomedical areas from about 1000 universities. More than 320 students participated in various courses (50% from EFPIA companies) in Provided 20 new courses in drug safety sciences. 58 students are following the flexible and fully e-learning programme covering medicines risk identification and quantification, medicines and public health, medicine risk communication, assessing the benefits of medicines, and regulatory processes. 24 universities network + 16 universities affiliates. 685 students have been following various courses (28% from EFPIA companies). Europe s first Patients Academy on Therapeutic Innovation aiming to provide scientifically reliable information on medicines and R&D, as well as an online public library that will empower patients to engage more effectively in the development and approval of new treatments and become true partners in pharmaceutical R&D.
42
43 Strategic Research Agenda for IMI2: The right prevention and treatment for the right patient at the right time Draft available at Comments and suggestions are welcome:
The Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationInnovative Medicines Initiative Sadallah Fatiha IMI JU Office, Brussels, Belgium
Innovative Medicines Initiative 2 2009-2014 Sadallah Fatiha IMI JU Office, Brussels, Belgium The Evolution of IMI: From bottlenecks in industry to bottlenecks in Industry and Society Make Drug R&D processes
More informationIMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager
IMI2: Strategic research agenda and overall approach Hugh Laverty Senior Scientific Project Manager Introducing IMI2: Vienna 16 July 2014 The way in which pharmaceutical companies develop new medicines
More informationJoint Technology Initiative: Innovative Medicine Initiative
Joint Technology Initiative: Innovative Medicine Initiative Dr John E Butler-Ransohoff Global External Innovation and Alliances Bayer HealthCare AG, Berlin/Wuppertal Bari, 30 April 2015 Largest Public
More informationEuropean Induced Pluripotent Stem Cell Bank
European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented
More informationThe Innovative Medicines Initiative Socio-economic impacts
The Innovative Medicines Initiative Socio-economic impacts Pierre Meulien, IMI Executive Director European Innovation Summit European Parliament 08.12.2015 Closed & open innovation Filing Approval HTA
More informationEU support for Health Research from FP6 to FP7
EU support for Health Research from FP6 to FP7 Stéphane Hogan Head of Biotechnology Unit Directorate for Health Research DG Research - European Commission Valencia - 15 September 2006 EU research programmes
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationWebinar IMI2 - Call 9 Data quality in preclinical research and development. Thomas Steckler IMI webinar
Webinar IMI2 - Call 9 Data quality in preclinical research and development Thomas Steckler 11.04.2016 IMI webinar Need for public-private collaboration Low quality data hamper innovation and progress in
More informationConsortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration
More informationForthcoming Calls for Proposals (10/11) Barcelona 28 June 2013
Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013 Indicative list Proposed topic /11 /11 /11 Identification and validation of innovative clinical endpoints for Osteoarthritis European genotype-phenotype
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationOpportunities for industry/smes in EU-funded health research
Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005
More informationWebinar IMI2 Call 14 Opportunities for SMEs
Webinar IMI2 Call 14 Opportunities for SMEs 19 March 2018 Agenda How to use GoToWebinar Catherine Brett, IMI Opportunities for SMEs Colm Carroll, IMI Questions & answers How to use GoToWebinar - audio
More informationA unique Collaborative Model for the Discovery of New Therapeutic Approaches
A unique Collaborative Model for the Discovery of New Therapeutic Approaches THE INNOVATION GAP OPEN INNOVATION TO ADDRESS THE LACK OF PRODUCTIVITY OF BIOPHARMACEUTICAL RESEARCH A PRE-COMPETITIVE PHARMA
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationRare diseases in the 7th EU Framework Programme for Research and Technological Development
Rare diseases in the 7th EU Framework Programme for Research and Technological Development Manuel Hallen, MD Head of Unit Medical & Public Health Research DG Research European Commission 1 The role of
More information"Stratification biomarkers in personalised medicine"
1/12 2/12 SUMMARY REPORT "Stratification biomarkers in personalised medicine" Workshop to clarify the scope for stratification biomarkers and to identify bottlenecks in the discovery and the use of such
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationBIOCRATES Life Sciences AG Short Company Presentation
BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life
More informationBibliometric analysis of ongoing projects
Bibliometric analysis of ongoing projects 6 th report June 2015 Copyright 2014 Innovative Medicines Initiative Prepared by Thomson Reuters on behalf of IMI Programme Office under a public procurement procedure
More informationMaximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationTranslational Research
Translational Research Paddy Johnston Chair, MRC Translational Research Overview Group October 2012 Translational Research Strategy and its delivery To accelerate patient benefit and increase economic
More informationA French Biotechnology company dedicated to the development and production of human endocrine cell lines. Innovation In Healthcare April 2012
A French Biotechnology company dedicated to the development and production of human endocrine cell lines Innovation In Healthcare 16-17 April 2012 1 French Biotechnology company Founded in S2 2004 in Paris
More informationIBBL: Introduction to Biobanks and their services
IBBL: Introduction to Biobanks and their services HighTech meets Health, Oss (NL), 15 th June 2017 Monica Marchese, PhD Biomarker Validation Scientist AN ACCREDITED & CERTIFIED BIOBANK INFRASTRUCTURE FOR
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationNew Frontiers in Personalized Medicine
New Frontiers in Personalized Medicine Oracle Open World Shanghai 2013 Neil de Crescenzo SVP and GM 1 Safe Harbor Statement The following is intended to outline our general product direction. It is intended
More informationThe NHS approach to personalised medicine in respiratory disease. Professor Sue Chief Scientific Officer for England
The NHS approach to personalised medicine in respiratory disease Professor Sue Hill @CSOSue Chief Scientific Officer for England Jul 2017 Genomics is probably the biggest breakthrough in the last 50 years.
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More informationSSPPS STRATEGIC PLAN. Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice. April 30, Overview
SSPPS STRATEGIC PLAN Pharmacy Education, Pharmaceutical Sciences Research, Clinical Pharmacy Practice April 30, 2012 Overview Here we present the 2012-2017 strategic plan for the Skaggs School of Pharmacy
More informationBBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017
BBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017 BBMRI-NL TOWARDS A NATIONAL BIOBANKING INFRASTRUCTURE Founded in 2009 as the Dutch
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationThe Seventh Framework Programme ( )
The Seventh Framework Programme (2007-2013) Opportunities for Cardiovascular Research 1 Octavi Quintana Trias, MD, MPH Director Health DG Research - European Commission Octavi.Quintana-Trias@ec.europa.eu
More informationNovember 5 th, 2013 FOCUS 2014 COMPETITION
November 5 th, 2013 FOCUS 2014 COMPETITION A COLLABORATIVE APPROACH TO FOSTER BIOPHARMACEUTICAL R&D Vision To be a global leader actively involved in creating Canadian and International networks dedicated
More informationThe Five Key Elements of a Successful Metabolomics Study
The Five Key Elements of a Successful Metabolomics Study Metabolomics: Completing the Biological Picture Metabolomics is offering new insights into systems biology, empowering biomarker discovery, and
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationE2ES to Accelerate Next-Generation Genome Analysis in Clinical Research
www.hcltech.com E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research whitepaper April 2015 TABLE OF CONTENTS Introduction 3 Challenges associated with NGS data analysis 3 HCL s NGS Solution
More informationEU perspective: European procedure for Qualification of novel methodologies for medicine development. Elmer Schabel MD
EU perspective: European procedure for Qualification of novel methodologies for medicine development Elmer Schabel MD Nothing to disclose See: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/landing/ex
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationSMEs in IMI2 Calls for Proposals
SMEs in IMI2 Calls for Proposals Why should an SME participate in an IMI project? IMI projects are focused on translating excellent research into real world outcomes an opportunity for SMEs Unique collaborative
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationReflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development
1 2 3 24 June 2010 EMA/CHMP/641298/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationATIP Avenir Program 2018 Young group leader
ATIP Avenir Program 2018 Young group leader Important dates - October 17th (4 pm) 2017 : opening of the registrations online - November 23 th 2017: deadline for the online submission, the mailing of the
More informationTechnology Development Funding Program Round 3
Technology Development Funding Program Round 3 CWRU January 26, 2015 1 Program Overview NIH Center for Accelerated Innovations (NCAI) at Cleveland Clinic Mission to improve translation of basic science
More informationFive years as EMA Liaison at US FDA
Five years as EMA Liaison at US FDA TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Dr Sabine Haubenreisser on 2 October 2017 European Medicines
More informationTOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS
TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER
More informationThe Integrated Biomedical Sciences Graduate Program
The Integrated Biomedical Sciences Graduate Program at the university of notre dame Cutting-edge biomedical research and training that transcends traditional departmental and disciplinary boundaries to
More informationEpidemiology in the era of digital data. Andrew Roddam September 2017
Epidemiology in the era of digital data Andrew Roddam September 2017 There are four big decisions in making medicines Molecule Target Clinical biological experiment Demonstration of clinical effect and
More informationResearch Strategy Delivering internationally excellent research for a healthy, safe and sustainable society
Research Strategy 2016-2018 Delivering internationally excellent research for a healthy, safe and sustainable society Mission The College of Biomedical and Life Sciences aims to deliver internationally
More informationDelivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
More informationDecision Process for Committing to a Therapeutic Development Approach: Target Validation Metrics and Biomarkers
Decision Process for Committing to a Therapeutic Development Approach: Target Validation Metrics and Biomarkers Kalpana Merchant, PhD Chief Scientific Officer, Tailored Therapeutics - Neuroscience Eli
More informationict Multi-Year Grants Funding Opportunity
ict Multi-Year Grants Funding Opportunity Overview Background Strategy for Patient- Oriented Research (SPOR) Innovative Clinical Trials initiative (ict) SPOR and JDRF Partnership on Innovative Clinical
More informationA gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationWITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT
WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges
More informationRare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
More informationThe 100,000 Genomes Project Genomics Collaboration Event Finnish Residence
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary
More informationPROACTIVE PHARMACOVIGILANCE
PROACTIVE PHARMACOVIGILANCE RISK BENEFIT A New Model for the 21st Century 21st century technologies will create significant opportunities and challenges for all health care stakeholders. Pharmacovigilance
More informationUsing local RWD to drive global therapeutic advancements.
Using local RWD to drive global therapeutic advancements. Helsinki, 30 th Nov 2016 Mike Spencer, Head of Real World Evidence, EMEA, Janssen The following represent my own views and not necessarily those
More informationEU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective
EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development
More informationImproving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre
Improving Pa-ent Outcomes with Research: The Appliance of Science NIHR UCL Hospitals Biomedical Research Centre Bryan Williams MD FRCP FESC FAHA Professor of Medicine and BRC Director 29/08/2013 Creating
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationHD Regulatory Science Consortium (HD-RSC) A consortium aimed at accelerating treatments for Huntington s disease
HD Regulatory Science Consortium (HD-RSC) A consortium aimed at accelerating treatments for Huntington s disease Critical Path Institute / CHDI Foundation Huntington s Disease Regulatory Science Consortium
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationMAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE
MAYO CLINIC CENTER FOR BIOMEDICAL DISCOVERY EXCEPTIONAL RESEARCH LEADS TO EXCEPTIONAL PATIENT CARE THE RESEARCH WE DO TODAY WILL DETERMINE THE TYPE OF MEDICAL AND SURGICAL PRACTICE WE CARRY ON AT THE CLINIC
More informationFCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)
FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du) Course BIOMARKERS AND ASSAY DEVELOPMENT February 6-10, 2017 Faculty of Pharmacy Amphitheatre B Universidade de Lisboa, Portugal The FCT
More informationThe Evolution of SDTM
The Evolution of SDTM What s new? Tina Apers CRO Manager Mobile +32 476 60 08 79 tina.apers@businessdecision.com Business & Decision Life Sciences Tel +32 2 774 11 00 Fax +32 2 774 11 99 Sint-Lambertusstraat
More informationEARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles
EARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles BrainDTech team Dr. Fabio Bianco, PhD Chief Executive Officier PhD in Pharmacology, Degree in Biotech
More informationIntroducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration
Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration 1 2 Translational Informatics Overview Precision s suite of services is
More informationMOSAIQUES DIAGNOSTICS
MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development
More informationResearch and development case study. Human health research
Research and development case study Human health research November 2017 Introduction This case study on human health research is one of a series that we have developed to support and complement our published
More informationOrgans on Chips: The Future of Translational Research
Organs on Chips: The Future of Translational Research KRISTIN FABRE, PHD SCIENTIFIC PROGRAM MANAGER NIH NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCE (NCATS) 1 Advancing regulatory sciences Drug
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationGenomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)
Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Strategies for modern biomarker and drug - Oct 3, 2014 Sequencing the cancer genome
More informationJanssens Discovery Data Integrity program (DDI): A journey over the last 7 years Research Integrity: Position yourself for success!
Janssens Discovery Data Integrity program (DDI): A journey over the last 7 years Research Integrity: Position yourself for success! David J. Gallacher, PhD DDI Co-Lead, Global Head of Safety Pharmacology
More informationHorizon 2020 Health Summit-IIS La Fe. Valencia, 12 de diciembre de 2017
Horizon 2020 Health Summit-IIS La Fe Valencia, 12 de diciembre de 2017 2 History 3 AsphaTeam +75 members Consultants with Life Science Background 20 team members with PhD High knowhow in drug development
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationHealthy Ageing. From Basic Science to Clinical Applications and New Business. Jan Sikkema Center for Development and Innovation June 16, 2016
Healthy Ageing From Basic Science to Clinical Applications and New Business Jan Sikkema Center for Development and Innovation June 16, 2016 Groningen Broad Research University 11 faculties > 30.000 students
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationThe Future of Clinical and Pharmaceutical Research
The Future of Clinical and Pharmaceutical Research Petra Streng, Industry Business Unit Life Sciences, SAP AG Dr. René Fitterer, Public Services & Healthcare, SAP (Switzerland) Inc. SAP Forum Basel, 20
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationReduce costs of the early drug development process Increase probality of developing drugs that enter late clinical phases
Aktivitetsplan 5 - Application for Strategic collaboration on joint development and implementation of service offerings between Bioneer A/S and Fraunhofer Institute for Biomedical Engineering (Særskilt
More informationThis video gives an overview of the centralised procedure at the European Medicines Agency
This video gives an overview of the centralised procedure at the European Medicines Agency In Europe today, all medicines must have a marketing authorisation before they can be used by patients And there
More information+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA
At the Center for Infectious Disease Research, we use systems biology approaches and cutting-edge technologies to accelerate the development of life-saving drugs, diagnostics and treatments for the world
More informationPreclinical models of negative symptoms and their implications for clinical trials. Martien Kas
Preclinical models of negative symptoms and their implications for clinical trials Martien Kas From diagnose to biology ISCTM ~ ECNP Joint Conference 1 September 2017 Paris France The road to restoring
More informationUpdate on Real World Evidence Data Collection
Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large
More information7 Sexual Health.
RESE ARCH & DEVELOPMENT 22 Highlights Signed an agreement with Medicines for Malaria Venture (MMV) to provide MMV with access to the Pfizer library of novel chemical entities to screen for compounds that
More informationType of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
More information